Edition:
United States

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

87.00USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$87.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
105,257
52-wk High
$87.80
52-wk Low
$31.70

Chart for

About

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and... (more)

Overall

Beta: -0.10
Market Cap(Mil.): $2,953.76
Shares Outstanding(Mil.): 37.04
Dividend: --
Yield (%): --

Financials

  FMI.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -4.21 -- --
ROI: -120.21 -8.07 12.63
ROE: -209.94 -10.87 14.50

BRIEF-Foundation Medicine Q1 Loss Per Share $1.02

* FOUNDATION MEDICINE ANNOUNCES 2018 FIRST QUARTER RESULTS AND RECENT HIGHLIGHTS

May 02 2018

BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche

* SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB Further company coverage: (Reporting by Hong Kong newsroom)

Apr 26 2018

BRIEF-Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. FDA

* FOUNDATION MEDICINE'S NEW LIQUID BIOPSY ASSAY GRANTED BREAKTHROUGH DEVICE DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION

Apr 26 2018

BRIEF-Foundation Medicine - Co, Guardant Health ‍Announced Agreement To Settle False Advertising Challenges

* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ‍ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 13 2018

BRIEF-Foundation Medicine Reports Qtrly ‍loss Per Share $1.05

* FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK

Mar 07 2018

BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd

* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING

Mar 05 2018

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

Jan 16 2018

BRIEF-Foundation Medicine Reports Preliminary 2017 Results

* - ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​

Jan 08 2018

BRIEF-Foundation Medicine Files For Potential Mixed Shelf, Size Not Disclosed

* FOUNDATION MEDICINE INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2BO42UB) Further company coverage:

Dec 22 2017

Foundation's cancer gene test gets U.S. FDA and Medicare nod

CHICAGO A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.

Nov 30 2017

Earnings vs. Estimates